ES2183567T3 - Inhibidores de fkbp. - Google Patents
Inhibidores de fkbp.Info
- Publication number
- ES2183567T3 ES2183567T3 ES99926683T ES99926683T ES2183567T3 ES 2183567 T3 ES2183567 T3 ES 2183567T3 ES 99926683 T ES99926683 T ES 99926683T ES 99926683 T ES99926683 T ES 99926683T ES 2183567 T3 ES2183567 T3 ES 2183567T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkyl
- halo
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Glass Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de fórmula (I): o una sal farmacéuticamente aceptable, o solvato de cualquiera de los mismos, en la que: X es O, S, NH o N(alquilo C1-6); cada uno de R1, R2, R3 y R4 es independientemente H, OH, OCO(alquilo C1-6), CO2(alquilo C1-6), CONH2, CONH(alquilo C1-6), CON(alquilo C1-6)2, halo, cicloalquilo C3-7, cicloalquiloxi C3-7, alquenilo C2-6, arilo1, alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados entre halo y cicloalquilo C3-7 y alcoxi C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados entre fluoro y cicloalquilo C3-7; A es un alquileno C3-5 no ramificado opcionalmente sustituido con hasta tres grupos alquilo C1-6; D es O o S; E es O, S, NH, N(alquilo C1-6) o CR11R12; G es alquilo C1-14 o alquenilo C2-14, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre halo, arilo, alcoxi C1-14, cicloalquilo, het y NR5R6, cada uno de R5 y R6 es independientemente H o alquilo C1-6 o se toman conjuntamente para formar, con el átomo de nitrógeno al que están unidos, un anillo heterocíclico de 4 a 7 miembros que contiene opcionalmente otro resto hetero seleccionado entre NR7, O y S(O)P y estando dicho anillo heterocíclico de 4 a 7 miembros opcionalmente sustituido con hasta 3 sustituyentes seleccionados independientemente entre alquilo C1-6 y alcoxi C1-6; R7 es H, alquilo C1-6, alquenilo C2-6, COR8, SO2R8, CONR9R10, CO2R8 o SO2NR9R10; R8 es cicloalquilo C3-7, alquenilo C2-6, arilo1 o alquilo C1-6 opcionalmente sustituidos con cicloalquilo C3- 7 o arilo1; cada uno de R9 y R10 es independientemente H, alquenilo C2-6, cicloalquilo C3-7 o alquilo C1-6 opcionalmente sustituido con cicloalquilo C3-7 o arilo; cada uno de R11 y R12 es independientemente H, arilo, alquenilo C2-8 o alquilo C1-8, estando dichos grupos alquenilo C2-8 y alquilo C1-8 opcionalmente sustituidos con unoo más sustituyentes seleccionados independientemente entre halo, NO2, alquilo C1-6, alquenilo C2-6, cicloalquilo, OH, alcoxi C1-6, alqueniloxi C2-6, feniloxi, benciloxi, NH2, arilo y het; p es 0,1 ó 2; en las que "arilo" significa fenilo o naftilo, y cada uno de ellos está opcionalmente sustituido con hasta 3 sustituyentes seleccionados independientemente entre alquilo C1-6 opcionalmente sustituido con uno o más grupos halo o cicloalquilo C3-7, alquenilo C2-6, alcoxi C1-6, alqueniloxi C2-6, OH, halo, NO2, feniloxi, benciloxi, fenilo y NH2; "arilo" significa fenilo, naftilo o bencilo, en las que cada uno de ellos está opcionalmente sustituido con 1 ó 2 sustituyentes seleccionados independientemente entre alquilo C1-6 opcionalmente sustituido con uno o más grupos halo o cicloalquilo C3-7, alcoxi y halo; siendo "cicloalquilo" cicloalquilo C3-8 opcionalmente sustituido con hasta 3 sustituyentes seleccionados independientemente entre alqueniloC2-6, alcoxi C1-6, alqueniloxi C2-6, OH, halo y alquilo C1-6 opcionalmente sustituido con uno o más halo; y significando "het" un heterociclico monocíclico de 5 ó 6 miembros o bicíclico de 8, 9 ó 10 miembros que contiene de 1 a 3 heteroátomos seleccionados independientemente entre O, N y S y que está opcionalmente sustituido con hasta 3 sustituyentes seleccionados independientemente entre alquilo C1-6 opcionalmente sustituido con uno o más grupos halo o cicloalquilo C3-7, alquenilo C2-6, alcoxi C1-6, alqueniloxi C2-6, OH, halo, NO2, feniloxi, benciloxi y NH2; con la condición de que el compuesto no sea metil 1- (5-cloro-2-benzoxazolil)prolina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815696.1A GB9815696D0 (en) | 1998-07-20 | 1998-07-20 | Heterocyclics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2183567T3 true ES2183567T3 (es) | 2003-03-16 |
Family
ID=10835773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99926683T Expired - Lifetime ES2183567T3 (es) | 1998-07-20 | 1999-07-01 | Inhibidores de fkbp. |
Country Status (45)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| GB0008939D0 (en) | 2000-04-11 | 2000-05-31 | Glaxo Group Ltd | Process for preparing substituted benzimidazole compounds |
| AU2002241524A1 (en) * | 2000-11-28 | 2002-06-11 | Wyeth | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| US7186518B2 (en) * | 2003-11-21 | 2007-03-06 | Dade Behring Inc. | Method and composition useful for determining FK 506 |
| WO2009154754A2 (en) * | 2008-06-17 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| TWI534142B (zh) | 2011-03-15 | 2016-05-21 | 大正製藥股份有限公司 | Azole derivatives |
| EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
| CN106138044B (zh) * | 2016-07-15 | 2017-05-03 | 鲁俊东 | 一种治疗腰椎间盘突出症的药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI91859C (fi) * | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
| FR2696176B1 (fr) * | 1992-09-28 | 1994-11-10 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
| CO4520280A1 (es) * | 1993-10-26 | 1997-10-15 | Boehringer Ingelheim Pharma | Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos |
| US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
| GB9700597D0 (en) * | 1997-01-14 | 1997-03-05 | Sandoz Pharma Uk | Organic compounds |
| US5721256A (en) * | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| US6686357B1 (en) * | 1999-07-15 | 2004-02-03 | Pfizer, Inc. | FKBP inhibitors |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
-
1998
- 1998-07-20 GB GBGB9815696.1A patent/GB9815696D0/en not_active Ceased
-
1999
- 1999-01-07 UA UA2001010434A patent/UA60368C2/uk unknown
- 1999-06-30 HN HN1999000101A patent/HN1999000101A/es unknown
- 1999-07-01 NZ NZ508839A patent/NZ508839A/xx unknown
- 1999-07-01 BR BR9912307-0A patent/BR9912307A/pt not_active Application Discontinuation
- 1999-07-01 DE DE69903319T patent/DE69903319T2/de not_active Expired - Fee Related
- 1999-07-01 SI SI9930120T patent/SI1098894T1/xx unknown
- 1999-07-01 CZ CZ2001224A patent/CZ2001224A3/cs unknown
- 1999-07-01 YU YU83100A patent/YU83100A/sh unknown
- 1999-07-01 HU HU0103020A patent/HUP0103020A3/hu unknown
- 1999-07-01 OA OA1200100024A patent/OA11586A/en unknown
- 1999-07-01 EE EEP200100043A patent/EE200100043A/xx unknown
- 1999-07-01 AT AT99926683T patent/ATE225346T1/de not_active IP Right Cessation
- 1999-07-01 SK SK70-2001A patent/SK702001A3/sk unknown
- 1999-07-01 ES ES99926683T patent/ES2183567T3/es not_active Expired - Lifetime
- 1999-07-01 KR KR1020017000834A patent/KR20010083130A/ko not_active Application Discontinuation
- 1999-07-01 ID IDW20010154A patent/ID27022A/id unknown
- 1999-07-01 AP APAP/P/2001/002045A patent/AP2001002045A0/en unknown
- 1999-07-01 PT PT99926683T patent/PT1098894E/pt unknown
- 1999-07-01 CA CA002338276A patent/CA2338276C/en not_active Expired - Fee Related
- 1999-07-01 AU AU43855/99A patent/AU756769B2/en not_active Ceased
- 1999-07-01 DK DK99926683T patent/DK1098894T3/da active
- 1999-07-01 CN CN99810385A patent/CN1315951A/zh active Pending
- 1999-07-01 EA EA200100051A patent/EA200100051A1/ru unknown
- 1999-07-01 JP JP2000561187A patent/JP3545341B2/ja not_active Expired - Fee Related
- 1999-07-01 TR TR2001/00133T patent/TR200100133T2/xx unknown
- 1999-07-01 EP EP99926683A patent/EP1098894B1/en not_active Expired - Lifetime
- 1999-07-01 PL PL99345705A patent/PL345705A1/xx not_active Application Discontinuation
- 1999-07-01 WO PCT/IB1999/001227 patent/WO2000005231A1/en not_active Application Discontinuation
- 1999-07-01 IL IL14024399A patent/IL140243A0/xx unknown
- 1999-07-12 PA PA19998477601A patent/PA8477601A1/es unknown
- 1999-07-15 US US09/354,193 patent/US6166011A/en not_active Expired - Fee Related
- 1999-07-16 PE PE1999000722A patent/PE20000867A1/es not_active Application Discontinuation
- 1999-07-19 CO CO99045678A patent/CO5080761A1/es unknown
- 1999-07-19 DZ DZ990148A patent/DZ2848A1/xx active
- 1999-07-19 AR ARP990103543A patent/AR016501A1/es not_active Application Discontinuation
- 1999-07-19 TN TNTNSN99146A patent/TNSN99146A1/fr unknown
- 1999-07-19 GT GT199900113A patent/GT199900113A/es unknown
- 1999-07-19 MA MA25689A patent/MA26661A1/fr unknown
-
2000
- 2000-12-29 IS IS5799A patent/IS5799A/is unknown
-
2001
- 2001-01-09 ZA ZA200100229A patent/ZA200100229B/en unknown
- 2001-01-18 NO NO20010299A patent/NO20010299L/no not_active Application Discontinuation
- 2001-01-19 HR HR20010053A patent/HRP20010053A2/hr not_active Application Discontinuation
- 2001-02-14 BG BG105249A patent/BG105249A/xx unknown
-
2002
- 2002-03-26 HK HK02102302.7A patent/HK1040706A1/zh unknown
-
2003
- 2003-04-01 US US10/404,524 patent/US20040058905A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR055053A1 (es) | Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas. | |
| ES2183567T3 (es) | Inhibidores de fkbp. | |
| AR046083A1 (es) | Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos | |
| ES2255190T3 (es) | Compuestos indol 2,3-sustituidos como inhibidores de cox-2. | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR054045A1 (es) | Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| CO4940472A1 (es) | Pirazolopirimidonas para la disfuncion sexual | |
| AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
| AR037676A1 (es) | Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion; composicion farmaceutica que los comprende y procedimiento para preparar compuestos de formula (i) | |
| ES2271615T3 (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados y su uso como antibacterianos. | |
| AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| NI200800247A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
| AR048042A1 (es) | Inhibidores no nucleosidos de transcriptasa inversa y composiciones farmaceuticas | |
| CO5560575A2 (es) | Compuestos derivados de dihidro-pteridinonas caracterizados por ser inhibidores de especificas cinasas del ciclo celular y preparaciones farmaceuticas que los contienen | |
| AR037816A1 (es) | Fenil derivados sustituidos | |
| ES2258642T3 (es) | Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina. | |
| AR049346A1 (es) | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas | |
| AR054529A1 (es) | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 | |
| BR0109547A (pt) | teres difenìlicos utilizados em terapêutica |